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Abstract
Aims/hypothesis Mutations in the GCK and HNF1A genes
are the most common cause of the monogenic forms of
diabetes known as ‘maturity-onset diabetes of the young’.
GCK encodes the glucokinase enzyme, which acts as the
pancreatic glucose sensor, and mutations result in stable,
mild fasting hyperglycaemia. A progressive insulin secre-
tory defect is seen in patients with mutations in the HNF1A
and HNF4A genes encoding the transcription factors
hepatocyte nuclear factor-1 alpha and -4 alpha. A molecular
genetic diagnosis often changes management, since patients
with GCK mutations rarely require pharmacological treat-
ment and HNF1A/4A mutation carriers are sensitive to
sulfonylureas. These monogenic forms of diabetes are often
misdiagnosed as type 1 or 2 diabetes. Best practice
guidelines for genetic testing were developed to guide
testing and reporting of results.
Methods A workshop was held to discuss clinical criteria
for testing and the interpretation of molecular genetic test
results. The participants included 22 clinicians and scien-
tists from 13 countries. Draft best practice guidelines were
formulated and edited using an online tool (http://www.
coventi.com).
Results An agreed set of clinical criteria were defined for
the testing of babies, children and adults for GCK, HNF1A
and HNF4A mutations. Reporting scenarios were discussed
and consensus statements produced.
Conclusions/interpretation Best practice guidelines have
been established for monogenic forms of diabetes caused
by mutations in the GCK, HNF1A and HNF4A genes. The
guidelines include both diagnostic and predictive genetic
tests and interpretation of the results.
Keywords Best practice .GCK .HNF1A .HNF4A .
Maturity-onset diabetes of the young .MODY.
Monogenic diabetes
Abbreviations
CSCE conformation-sensitive capillary electrophoresis
dHPLC denaturing high-performance liquid
chromatography
SNP single nucleotide polymorphism
Introduction
Maturity-onset diabetes of the young (MODY) describes
the dominantly inherited disorder of non-insulin-dependent
diabetes typically diagnosed before 25 years that was first
recognised by Tattersall [1, 2]. MODY is the most common
form of monogenic diabetes, accounting for an estimated
1–2% of diabetes in Europe [3, 4], but is often misdiag-
nosed as type 1 or type 2 diabetes.
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The term MODY is used to describe a group of clinically
heterogeneous, often non-insulin-dependent forms of diabetes
that are defined at the molecular genetics level bymutations in
different genes. All show dominant inheritance and are
disorders of beta cell dysfunction, but variable features
include the age at onset, severity of the hyperglycaemia (and
hence risk of complications) and associated clinical features.
The most recent classification of diabetes by the American
Diabetes Association and the World Health Organization
recognises these discrete subtypes of MODY [5].
Mutations in the GCK and HNF1A genes are the most
frequent cause of MODY in all populations studied. They
account for approximately 70% of cases (see Table 1). The
ratio of GCK to HNF1A mutations varies between countries
because of different recruitment strategies for genetic
testing; blood glucose screening in young, asymptomatic
individuals will identify a higher proportion of GCK
mutations.
Heterozygous loss-of-function GCK mutations result in
mild, stable hyperglycaemia from birth. Microvascular
complications are rare, reflecting the fact that HbA1c is
normally just above the upper limit of the normal range.
Treatment with oral hypoglycaemic agents or insulin is not
needed because it rarely changes HbA1c [6]. A genetic
diagnosis is important for the small number of children
misdiagnosed with type 1 diabetes and treated with insulin
[7]. The identification of GCK mutations in women with
gestational diabetes can be useful for obstetric management,
since their babies who do not inherit the mutation are at risk
of macrosomia [8], and it can guide follow-up in the
mothers.
Transcription factor mutations in the HNF1A or HNF4A
genes cause a similar progressive diabetic phenotype
although the penetrance of HNF4A mutations is lower (S.
Ellard and A. T. Hattersley, unpublished data). Sensitivity
to sulfonylureas means that some patients can transfer from
insulin to oral agents [9, 10]. A low renal threshold for
glucose is a feature of HNF1A mutations [11] and may
provide a useful method of screening at-risk family
members during childhood [12].
Mutations identified in the GCK, HNF1A and HNF4A
genes include missense, nonsense, splicing, small deletions/
insertions/duplications, and splice site and promoter region
mutations [13, 14]. Partial and whole deletions have
recently been reported in HNF1A and GCK [15]. The
location of mutations within the HNF1A gene influences
the age at diagnosis; the average age at diagnosis for
patients with exon 1–6 mutations that affect all three
HNF1A isoforms is younger than for those with mutations
in exons 8–10 that affect only isoform HNF1A(A) [16, 17].
Rarer forms of MODY include heterozygous mutations
in PDX1 (also known as IPF1; [18, 19]) and NEUROD1
[20, 21], but analysis of these genes is not usually included
in routine molecular genetic testing for MODY. Dominantly
Table 1 Genes in which mutations cause MODY
Gene symbol (other symbol)
GCK HNF1A (TCF1) HNF4A PDX1 (IPF1) NEUROD1 HNF1B
(TCF2)
Protein Glucokinase Hepatocyte
nuclear factor-1
alpha
Hepatocyte
nuclear factor-4
alpha
Insulin
promoter
factor-1
Neurogenic
differentiation
1
Hepatocyte
nuclear
factor-1 beta
Chromosome locus 7p13 12q24.31 20q13.12 13q12.2 2q31.3 17q12
Gene Accession no. NM_000162.2 NM_000545.4 NM_000457.3a NM_000209.2 NM_002500.2 NM_000458.1
OMIM * (Gene) 138079 142410 600281 600733 601724 189907
OMIM # (Phenotype) 125851 600496 125850 606392 606394 137920
Mutation frequency (%) (not
known in ~20% of cases)
20–50 20–50 ~5 <1 <1 ~5
The Genbank reference sequence NM_000457.3 refers to the full length P1 transcript, which uses exons 1a and 1b, and not 1d. For the full length
P2 transcript, which includes exon 1d, there is a human mRNA sequence AY680697 but no refseq. The convention is to use NM_000457.3 for
exons 1a/1b and 2–10, with AY680697 for exon 1d only. HNF4A mutation descriptions in the literature use the translation start codon reported by
Chartier et al. in 1994 [45]. However, an alternative start codon nine amino acids upstream was proposed in 1996 [46] and this alternative start
codon is used in NM_000457.3. Hence the convention is to report HNF4A mutations using the amino acid methionine at codon 10 in
NM_000457.3 as the start codon, with the A of this codon as the first nucleotide
a Nomenclature for the HNF4A gene is complicated because the gene encodes nine isoforms expressed from two promoters. The liver-specific P1
promoter drives the expression of transcripts 1–3, which include exons 1a and 2–10, and transcripts 4–6, which include exons 1a, 1b, 1c and 2–10.
Transcripts 7–9 are expressed from the pancreatic (P2) promoter located approximately 46 kb upstream of the HNF4A transcription start site and
exhibit splicing of the upstream exon 1d to exon 2, without the inclusion of sequences from either exons 1a, 1b or 1c
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inherited syndromic forms of diabetes may also be
described as MODY subtypes. The renal cysts and diabetes
syndrome results from HNF1B mutations, and other
features include renal abnormalities, female genital mal-
formations, hyperuricaemia, pancreatic atrophy and ab-
normal liver function tests [22–24]. Mutations in the CEL
variable number tandem repeat cause a syndrome of
diabetes and pancreatic exocrine dysfunction [25]. These
syndromes and maternally inherited diabetes and deafness
caused by the mitochondrial m.3243A→G mutation are
not included in these guidelines since testing is guided
by the non-endocrine pancreatic or extra-pancreatic
clinical features.
A molecular genetic diagnosis of a GCK, HNF1A or
HNF4A mutation is important because it confirms a
diagnosis of MODY, classifies the subtype, predicts the
likely clinical course and may change the patient’s
treatment. First-degree relatives will be at 50% risk of
inheriting the mutation and asymptomatic individuals may
be offered predictive genetic testing (after appropriate
genetic counselling) in order to provide reassurance (for
those shown not to carry the mutation) or regular blood
glucose monitoring with early diagnosis and appropriate
treatment (for mutation carriers).
Methods
A group of European clinicians and scientists met on 22
May 2007 at a workshop to formulate best practice
guidelines for molecular genetic testing in MODY. Dis-
cussions focused on clinical criteria for selection of patients
for testing, methodologies, interpretation of results and
reporting those results to the referring clinicians.
A draft document was posted on 24 August 2007 and an
online editing tool was used by participants to produce
consensus guidelines.
Results
Clinical criteria for testing
Mild fasting hyperglycaemia: testing for GCK mutations
The finding of raised fasting blood glucose in the range of
5.5–8 mmol/l is unusual in children and young adults.
This always raises concern that they may be about to
develop type 1 diabetes or the patient has type 2 diabetes.
However, a considerable proportion of young, non-obese
patients with persistent mild fasting hyperglycaemia will
have a heterozygous mutation in the GCK gene. In a
cohort of 82 children with incidental hyperglycaemia, 43%
had GCK mutations [26]. The phenotype associated with
GCK mutations is remarkably similar for all mutations.
The following features suggest a diagnosis of a GCK
mutation:
1. The fasting hyperglycaemia is ≥5.5 mmol/l (98%
patients), persistent (at least three separate occasions)
and stable over a period of months or years [27].
2. HbA1c is typically just above the upper limit of normal
and rarely exceeds 7.5%.
3. In an OGTT the increment [(2 h glucose) − (fasting
glucose)] is small (71% of patients in the large European
study reported by Stride et al. [27] had an increment
<3 mmol/l). An increment of 4.6 mmol/l is often used to
prioritise testing and corresponds to the 90th centile (S.
Ellard and A. T. Hattersley, unpublished data).
4. Parents may have ‘type 2 diabetes’ with no complica-
tions or may not be diabetic. On testing, one parent will
usually have a mildly raised fasting blood glucose
(range of 5.5–8 mmol/l) unless the mutation has arisen
de novo. Testing of apparently unaffected parents’
fasting glucose is important when considering a
diagnosis of a glucokinase mutation.
Gestational diabetes: testing for GCK mutations Mutations
of GCK cause mild fasting hyperglycaemia throughout life
and this is often diagnosed during pregnancy when routine
testing is performed. Since these patients have consistently
raised fasting blood glucose levels, their babies who do not
inherit the mutation may be macrosomic [28]. The
diagnosis of a GCK mutation is important, not only as the
child may subsequently be picked up as having a raised
fasting blood glucose and this may lead to concern about
type 1 diabetes, but also because the guidelines given to the
mother are different from the normal ‘pre-type 2’ diabetic
phenotype as they will not deteriorate with time. The
following criteria identify when GCK testing is appropriate
[29]:
1. Persistently raised fasting blood glucose in the range of
5.5–8 mmol/l before, during and after pregnancy.
2. An increment of <4.6 mmol/l on at least one OGTT
(either during or after pregnancy).
3. A parent may have mild type 2 diabetes but often this
has not been detected and so the absence of family
history should not exclude the diagnosis.
Children and young adults with diabetes and a strong family
history of diabetes: testing for HNF1A mutations The
possibility of monogenic diabetes should be considered
whenever a parent has diabetes even if they are thought to
have type 1 or type 2 diabetes. The most common form of
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MODY is caused by HNF1A mutations. The clinical char-
acteristics of patients with HNF1A mutations include:
1. Young-onset diabetes (typically before 25 years old in
at least one family member).
2. Non-insulin-dependent outside the normal honeymoon
period (3 years), e.g. not developing ketoacidosis in the
absence of insulin, good glycaemic control on less than the
usual replacement dose of insulin, or detectable C-peptide
measured when on insulin with glucose >8 mmol/l.
3. Family history of diabetes (at least two generations).
This may be insulin treated and considered to be ‘type
1’ diabetes or ‘type 2’ diabetes. At least two individuals
within the family would typically be diagnosed in their
20s or 30s. There may also be an affected grandparent,
although often these are diagnosed after 45 years.
OGTTs in early stages tend to show a very large
glucose increment, usually >5 mmol/l [27]. Some
individuals may have a normal fasting level but a value
within the diabetic range at 2 h.
4. The absence of pancreatic islet autoantibodies.
5. Glycosuria at blood glucose levels <10 mmol/l is often
seen, as these patients have a low renal threshold [11].
6. Marked sensitivity to sulfonylureas resulting in hypo-
glycaemia despite poor glycaemic control before start-
ing sulfonylureas [9, 30].
7. Several features suggesting monogenic diabetes rather
than a diagnosis of young-onset type 2 diabetes should
be considered: no marked obesity or evidence of insulin
resistance in diabetic family members, absence of
acanthosis nigricans and whether the family is from
an ethnic background with a low prevalence of type 2
diabetes (e.g. of European descent).
Children and young adults with diabetes and a strong
family history of diabetes: testing for HNF4A mutations
Diabetes caused by mutations in the HNF4A gene is
considerably less common (Table 1) than HNF1A muta-
tions. The clinical characteristics are similar, except there is
not a low renal threshold and the age of diagnosis may be
later [31]. HNF4A mutations should be considered when
HNF1A analysis does not detect a mutation but the clinical
features are strongly suggestive of HNF1A. Patients are
often sensitive to sulfonylureas [32]. HNF4A mutations are
associated with macrosomia (approximately 56% of muta-
tion carriers) and transient neonatal hypoglycaemia (ap-
proximately 15% of mutation carriers) [33, 34]. The
possibility of HNF4A mutations should be considered when
diabetic family members have marked macrosomia
(>4.4 kg at term) or if diazoxide-responsive neonatal hyper-
insulinism has been diagnosed in the context of familial
diabetes.
Babies with diazoxide-responsive neonatal hyperinsulinae-
mic hypoglycaemia and a strong family history of diabetes:
testing for HNF4A mutations Mutations of HNF4A are a
cause of neonatal hypoglycaemia that remits during infancy
or early childhood, with diabetes developing later in life
[34]. Macrosomic babies with diazoxide-responsive hyper-
insulinism and a strong family history of diabetes (see
characteristic 3 in the section above entitled Children and
young adults with diabetes and a strong family history of
diabetes: testing for HNF1A mutations) should be consid-
ered for HNF4A mutation screening.
Testing methodology
The mutation screening methodology should be described
in the report [e.g. sequencing, denaturing high-performance
liquid chromatography (dHPLC), conformation-sensitive
capillary electrophoresis (CSCE)] together with the sensi-
tivity. PCR primers should be checked for primer binding
site single nucleotide polymorphisms (SNPs; a useful tool
is available at http://ngrl.man.ac.uk/SNPCheck/index.html).
Gene dosage analysis may be useful if a diagnosis of
MODY is strongly suspected and no mutation is found on
mutation screening.
Interpretation of results
The textbox includes recommended interpretations for the
most common reporting scenarios.
Reporting
Each laboratory has its own reporting format and general
guidance on reporting is available from the European Molec-
ular Genetics Quality Network (http://www.emqn.org), the UK
Clinical Molecular Genetics Society (http://www.cmgs.org)
and the Swiss Society of Medical Genetics (http://www.ssgm.
ch). A one page report is the preferred format.
The report should state the methodology and specify the
gene, exons and/or mutations tested for. If promoter
sequences are examined then the report should specify the
nucleotides analysed. An estimation of the assay sensitivity
is particularly useful for pre-screening techniques such as
dHPLC, CSCE etc. The use of mutation nomenclature
approved by the Human Genome Variation Society (http://
www.hgvs.org/mutnomen) is strongly recommended. The
gene accession number (with version) is required in order to
describe mutations unambiguously (see Table 1). The A
nucleotide of the ATG start codon is numbered +1.
Reports describing novel variants should state that the
variant is novel and include the evidence in support of
pathogenicity. This might include the absence from a large
series of ethnically matched controls or MODY patients
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(testing of 210 normal chromosomes is necessary to
achieve at least 80% power to detect a polymorphism
present in 1% of the population [35]). Testing of other
affected relatives is recommended in order to check for co-
segregation and to calculate the LOD score in suitable sized
pedigrees (LOD scores of ≥1 or ≥3 are suggestive or
conclusive of linkage, respectively).
For missense variants the evidence for pathogenicity
might include conservation across species and a significant
amino acid substitution. Several programs are available that
predict the pathogenicity of a missense variant based upon
amino acid conservation (SIFT; http://www.blocks.fhcrc.
org/sift/SIFT.html) or the structure and function of the
protein (PolyPHEN; http://www.genetics.bwh.harvard.edu/
pph) but they should be used to supplement other pieces of
evidence rather than in isolation.
Both missense and silent variants can affect splicing
if the mutation is within an exon splicing enhancer or
exon splicing silencer. Splice predictor software pro-
grams (http://www.fruitfly.org or http://rulai.cshl.edu/
cgi-bin/tools/ESE3/esefinder.cgi?process=home) may aid
interpretation. Base substitutions affecting the conserved
splice donor (GT) site, splice acceptor (AG) site or the
conserved A nucleotide within the branch site are highly
likely to be pathogenic but splice predictor software may
be useful in the interpretation of other intronic variants.
Analysis of patient mRNA is often informative but
lymphoblastoid cell lines are usually required because of
the low levels of expression of the MODY genes in
blood. Sequence analysis of RT-PCR products amplified
from lymphoblastoid cell mRNA has demonstrated exon
skipping, retention and the use of cryptic splice sites for a
Reporting scenarios
Scenario Interpretation 
Affected proband (or relative), mutation identified
(nonsense, frameshift, conserved splice site or
previously reported missense mutation)
This result confirms a diagnosis of MODY, subtype GCK (or HNF1A or  
HNF4A). 
State that the mutation has been reported previously if appropriate (include  
the reference if space permits) 
Testing for relatives is now possible 
Affected proband (or relative), novel mutation
identified (likely to be pathogenica) 
This result is consistent with a diagnosis of MODY, subtype GCK (or 
HNF1A or HNF4A) 
State that the mutation is novel and include evidence for pathogenicity 
Suggest testing of other affected relatives to investigate co-segregation with 
diabetes/hyperglycaemia 
Affected proband (or relative), novel variant identified
(unlikely to be pathogenicb) 
State that a novel variant was identified but is thought unlikely to be 
pathogenic 
This result does not confirm a diagnosis of MODY, subtype GCK (or HNF1A 
or HNF4A) 
Include suggestions for further testing if appropriate 
Affected proband, no mutation identified This result does not confirm a diagnosis of MODY, subtype GCK (or HNF1A 
or HNF4A) 
Include suggestions for further testing if appropriate 
Neonate/infant affected with hypoglycaemia, HNF4A
mutation identified 
This result confirms/is consistent with a diagnosis of neonatal hypoglycaemia 
caused by an HNF4A mutation 
This child is genetically predisposed to MODY, subtype HNF4A  
Predictive test  , mutation presentc This patient is genetically predisposed to MODY, subtype GCK (or HNF1A 
or HNF4A) 
Predictive test, mutation absent The risk of this patient developing diabetes is reduced to that of the 
population 
aLikely to be pathogenic—not found in at least 210 ethnically matched control chromosomes and/or predicted to be pathogenic (e.g.
conserved amino acid or data from SIFT/polyPHEN/fruitfly, etc.). Local practice may vary regarding the reporting of novel variants but 
guidelines produced by the Clinical Molecular Genetics Society may serve as a useful reference 
bUnlikely to be pathogenic—little or no evidence to support pathogenicity 
cWe recommend that unaffected relatives are offered a biochemical test (fasting blood glucose for GCK mutations or OGTT
for HNF1A/HNF4A mutations). If the biochemical test is consistent with a diagnosis of diabetes or hyperglycaemia then the genetic test 
will be diagnostic, not predictive 
GCK, glucokinase; HNF1A, hepatocyte nuclear factor-1 alpha; HNF4A, hepatocyte nuclear factor-4 alpha 
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variety of intronic mutations in the GCK, HNF1A and
HNF1B genes [36–38].
Novel promoter variants may be investigated by exam-
ination of known transcription binding sites or by in vitro
transfection experiments [39–42]. They may also alter
mRNA expression levels, which may be measured by
allele-specific real-time PCR [43].
Polymorphisms
Some laboratories include details of polymorphisms detected
in the report. The reasons for doing this include: (1) making all
data available to the requesting clinician based on the rationale
that a polymorphism may later be reclassified as a mutation;
and (2) identifying heterozygous SNPs excludes a gene
deletion involving the exon(s) in question.
However, this information can cause confusion or even
misinterpretation of the result (A. T. Hattersley, unpublished
data) and it certainly adds to the length of the report. While in
some cases there may be reports in the literature of an
association with type 2 diabetes or reduced insulin secretion,
these polymorphisms do not cause MODY and we recom-
mend that they should be excluded from the report.
Treatment
Individual treatment recommendations are outside the
jurisdiction of a molecular genetics report since this is
the referring clinician’s responsibility. It is useful to
include an appropriate reference if there is evidence in
the literature for a particular treatment (e.g. low-dose
sulfonylureas in HNF1A/4A MODY) associated with the
genetic diagnosis.
Other issues
Genetic counselling should be provided for all asymptom-
atic individuals requesting predictive testing. We recom-
mend that unaffected relatives are offered a biochemical test
first (fasting blood glucose for GCK mutations or OGTT for
HNF1A/HNF4A mutations). If the biochemical test is
consistent with a diagnosis of diabetes or hyperglycaemia
then the genetic test will be diagnostic, not predictive.
For families requesting predictive testing for children
too young to provide informed consent, referral to a
specialist clinical genetics unit (or equivalent) is strongly
recommended. Reasons for testing children include (1) to
remove the uncertainty around the child’s status, and (2)
to assist with management, as a negative test would mean
that monitoring of blood glucose/glycosuria would not be
necessary [44].
Conclusions
Molecular genetic testing is useful in patients with MODY
because it confirms a diagnosis of monogenic diabetes,
predicts likely clinical course, defines risk for relatives and
determines treatment.
At the present time, molecular genetic testing for MODY is
relatively expensive and phenotypic selection prior to testing
is normal practice. With the development of new technologies
it is likely that these costs will decrease in time and that the
analysis of genes associated with monogenic diabetes may
become routine for all newly diagnosed patients. In the
meantime we hope that these guidelines will be useful in
determining which patients should be offered testing, and in
the interpretation and reporting of the test results.
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